ZANTAC 25
LOE ApproachingNDAORALTABLET, EFFERVESCENT
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 25 is an oral effervescent tablet approved in 1994 as an NDA by GSK. The specific indication and mechanism of action are not documented in available data. This product operates in a mature market segment with established clinical utility.
LOE Approaching
This product is in the final stages of its market exclusivity period; team size and hiring activity are likely contracting as preparation for generic competition begins.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZANTAC 25 currently has zero linked job openings, reflecting its LOE-approaching status and mature lifecycle. Career roles on this product are primarily defensive, focused on maximizing remaining exclusivity period and managing competitive/generic transition rather than growth expansion.
Brand ManagerProduct Manager
Worked on ZANTAC 25 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.